» Articles » PMID: 29416940

Tumor-associated Macrophages Remodeling EMT and Predicting Survival in Colorectal Carcinoma

Overview
Journal Oncoimmunology
Date 2018 Feb 9
PMID 29416940
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

The immune contexture, a composition of the tumor microenvironment, plays multiple important roles in cancer stem cell (CSC) and epithelial-mesenchymal transition (EMT), and hence critically influences tumor initiation, progression and patient outcome. Tumor-associated macrophages (TAMs) are abundant in immune contexture, however their roles in CSC, EMT and prognosis of colorectal cancer (CRC) have not been elucidated. In 419 colorectal carcinomas, immune cell types (CD68 macrophages, CD3, CD4 or CD8 T lymphocytes, CD20 B lymphocytes), EMT markers (E-cadherin and Snail) as well as the stem cell marker (CD44v6) were detected in tumor center (TC) and tumor invasive front (TF) respectively by immunohistochemistry. Tumor buds, that represent EMT phenotype, were also counted. It was found CD68 macrophages were the most infiltrating immune cells in CRC. By correlation analysis, more CD68 macrophages were associated with more CD44v6 expression (p < 0.001), lower Snail expression (p = 0.08) and fewer tumor buds (p < 0.001). More CD68 macrophages were significantly related to more CD3 T lymphocytes (p = 0.002), CD8 T lymphocytes (p < 0.001) and CD20 B lymphocytes counts (p = 0.004). Strong CD68 macrophages infiltration also predicted long term overall survival. CRC patients with more tumor buds had worse survival. However, strong CD68 macrophages infiltration could reverse the unfavorable results since patients with more tumor buds but increasing CD68 macrophages infiltration had the favorable outcome, similar to lower tumor buds groups. This study provided direct morphological evidence that tumor-associated macrophages in the invasive front play critical roles in fighting with the unfavorable results of tumor buds, thus resulting favorable outcomes for CRC patients.

Citing Articles

Matrix metalloproteinase-12 by M2 macrophages induced epithelial to mesenchymal transition in chronic rhinosinusitis with nasal polyps.

Park J, Shin J, Yang H, Kim T, Lee S, Shin O PLoS One. 2024; 19(12):e0313097.

PMID: 39739687 PMC: 11687655. DOI: 10.1371/journal.pone.0313097.


Tumor-Infiltrating Immune Cells in Colorectal Cancer.

Ferkel S, Holman E, Sojwal R, Rubin S, Rogalla S Neoplasia. 2024; 59:101091.

PMID: 39642846 PMC: 11665540. DOI: 10.1016/j.neo.2024.101091.


Natural compounds modulate the mechanism of action of tumour-associated macrophages against colorectal cancer: a review.

Yuan W, Zhang J, Chen H, Zhuang Y, Zhou H, Li W J Cancer Res Clin Oncol. 2024; 150(11):502.

PMID: 39546016 PMC: 11568041. DOI: 10.1007/s00432-024-06022-8.


Characterization of metastasis-specific macrophages in colorectal cancer for prognosis prediction and immunometabolic remodeling.

Hua Y, Ma X, Zhao X, Wei X, Mu X, Zhang X Sci Rep. 2024; 14(1):26361.

PMID: 39487182 PMC: 11530676. DOI: 10.1038/s41598-024-77248-2.


The correlation between cancer stem cells and epithelial-mesenchymal transition: molecular mechanisms and significance in cancer theragnosis.

Lei Z, Teng Q, Koya J, Liu Y, Chen Z, Zeng L Front Immunol. 2024; 15:1417201.

PMID: 39403386 PMC: 11471544. DOI: 10.3389/fimmu.2024.1417201.


References
1.
Hill A, Bolus W, Hasty A . A decade of progress in adipose tissue macrophage biology. Immunol Rev. 2014; 262(1):134-52. PMC: 4203421. DOI: 10.1111/imr.12216. View

2.
Edin S, Wikberg M, Oldenborg P, Palmqvist R . Macrophages: Good guys in colorectal cancer. Oncoimmunology. 2013; 2(2):e23038. PMC: 3601174. DOI: 10.4161/onci.23038. View

3.
Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

4.
Zlobec I, Lugli A . Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2011; 1(7):651-61. PMC: 3248128. DOI: 10.18632/oncotarget.199. View

5.
Nguyen L, Vanner R, Dirks P, Eaves C . Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012; 12(2):133-43. DOI: 10.1038/nrc3184. View